Escolar Documentos
Profissional Documentos
Cultura Documentos
SCHOOL OF MEDICINE
DEPARTMENT OF PATHOLOGY
THE KIDNEY - OBJECTIVES
1. Review normal histology of the kidney
2. Review the renal physiology
3. Special stains:
What is or what is the use?
a) Periodic Acid Schiff stain
b) Silver Impregnation stains
c) Immunofluorescence and immunoperoxidase
a) Electron microscopy
4. How is defined congenital anomaly of the kidney?
a) Describe agenesis of the kidney
a) Describe hypoplasia
b) What is ectopic kidneys?
c) What is a horseshoe kidney?
5. Describe the following cystic diseases of the kidney (See table 20-2, page
962 Robbins, 7 t h ed)
a) Cystic renal dysplasia
b) Autosomal dominant polycystic kidney disease
a) Autosomal recessive polycystic kidney disease
c) Cystic diseases of renal medulla
6. Describe the following glomerular syndromes:
a) Acute nephritic syndrome
b) Rapidly progressive GN
c) Nephrotic syndrome
d) Chronic renal failure
e) Asymptomatic hematuria or
proteinuria
7. What are the four basic tissue reactions?
8. What is?
a) Anti-GBM nephritis
b) Heymann's nephritis
c) Antibodies against planted antigens
9. What is circulating immune complex nephritis?
10. What is the etiology and pathogenesis of?
( see Robbins 7 t h edTable 20-6, page 975)
a) Acute poststreptococcal glomerulonephritis (proliferative)
b) Rapidly progressive (crescentic) glomeruionephritis (RPGN)
c) Membranous glomerulonephritis
d) Minimal change disease (MCD) (LIPOID NEPHROSIS)
e) Focal segmental glomerulonephritis (FSG)
a) Membranoproliferative glomerulonephritis (MMPGN)
f) IgA Nephropathy (Berger's disease)
g) Focal proliferative and necrotizing glomerulonephritis (focal GN)
11. What is chronic glomerulonephritis?
12. What are the light, fluorescence, and electron microscopy changes of the
glomerulonephritides ?
13. What are the most frequent clinical presentation of the
glomerulonephritides ?
DISEASES AFFECTING TUBULES AND INTERSTITIUM:
1.Acute tubular necrosis (ATN)
a)What is acute tubular necrosis?
a) What are the causes?
b)What is the pathogenesis?
b) Describe the morphologic changes of ATN.
2.Tubulointerstitial nephritis:
3.What characterizes these diseases?
a) What is pyelonephritis (PN) and urinary tract infection?
a) What is the etiology and pathogenesis?
2. Malignant tumors:
a) Renal cell carcinoma (Adenocarcinoma)
Whatis the morphology? Explain the difference betwen sporadic and hereditary
carcinomas.
What is the importance of the size?
What is the clinical course?
What is the cytogenetic and genetic of the renal cell carcinomas?
UROTHELIAL CARCINOMAS OF RENAL PELVIS, URINARY BLADDER, URETER AND
URETHRA.
1. Where are the locations of this type of tumors?
2. What are the environmental association with transitional cell carcinoma?
3.What is the classification and frequency of these tumors?
4.Malignant and Benign
5.Describe and explain squamous cell carcinoma of the urinary bladder.
6.What is the role of schistosoma haematobium in SCC of urinary bldder? Explain
adenocarcinoma of urinary bladder.
7.What is acute cystitis. What is
chronic cystitis?
8. What is squamous metaplasia?
9. What is glandular metaplasia?
10. What is Malakoplakia?
1. What is nephrosclerosis?
a) benign
b) malignant
2. What is renal artery stenosis?
DISEASES AFFECTING TUBULES AND INTERSTITIUM:
1. Acute tubular necrosis (ATN)
a) What is acute tubular necrosis?
b) What are the causes?
c) What is the pathogenesis?
d) Describe the morphologic changes of ATN.
2. Tubulointerstitial nephritis:
3. What characterizes these diseases?
a) What is pyelonephritis (PN) and urinary tract infection?
b) What is the etiology and pathogenesis?
4. Describe the morphology of acute pyelonephritis, papillary necrosis,
pyelonephrosis, and perinephric abscess.
a) What are the predisposing conditions?
5.Explain chronic pyelonephritis (CPN) and reflux nephropathy. Describe
the morphology of CPN.
6.Describe tubulointerstitial nephritis (TIN) induced by drugs and toxins. Explain the
pathogenesis and the morphology.
7. What is the difference between drug-induced interstitial nephritis and analgesic
abuse nephropathy?
8. What is Urate nephropathy?
9. What are the kidney manifestations of Multiple Myeloma?
10. What is nephrosclerosis?
Universidad Central del Caribe
GLOMERULAR DISEASES
GLOMERULAR SYNDROMES:
- Acute Nephritic Syndrome-
- Hematuria, azotemia, variable proteinuria, oliguria, edema and Hypertension.
- Rapidly progressive (crescentic) glomeruionephritis( RPGN) -
Acute nephritis, proteinuria, acute renal failure
- Nephrotic Syndrome-
- > 3.5 g proteinuria, hypoalbuminemia, hyperlipidemia, lipiduria
- Chronic Renal Failure-
- Azotemia with uremia progressing through the years
- Asymptomatic Hematuria-
- Glomerular hematuria
- Asymptomatic Proteinuria-
- Subnephrotic proteinuria
Prevalence (%) of the etiologies for Nephrotic Syndrome
Children Adults
Membranous GN 5 30
MCD or Lipoid Nephrosis 65 10
FSGS 10 35
MPGN 10 10
Other proliferative GN 10 15
Histologic Alterations
- Glomerular Hypercellularity
- four or more adjacent cells per tuft
- they may e secondary to mesangial, endothelial or epithelial cells - leukocytic
infiltration (PNHs, MO, LY
- Basement Membrane Thickening
- Special stains: PAS or PASM
- Crescents
- Are formed by proliferation of parietal epithelial cells
Intermixed with inflammatory cells and fibrin.
Acute Poststreptococcal (Proliferative) GN
- It appears 1-4 weeks after a streptococcal infection of the pharynx or skin
- It occurs most frequently in children six to ten years of age, adults of any age may be
affected.
- E&P: Most due to Group A beta-hemolytic streptococci
(Streptococcus S. Pyogenes, types 12, 4, 1 (90%); and other bacteria
- Laboratory findings:
- AS0 titers
- Complement C3
- Cryoglobulins in the serum
Post streptococcal GN
- Clinical presentation: Acute nephritic syndrome
- Pathogenesis: Antibody mediated: circulating or planted antigen
- LM: Diffuse proliferative GN, leukocyte infiltration (PMNs)
- IF: Granular IgG and C3 in GBM and Mesangium
- EM: Subepithelial humps
Goodpasture's Syndrome
- Clinical presentation: RPGN
- pathogenesis: anti-GBM COL4A3
- LM: Diffuse proliferative GN, crescents - IF: Linear IgG and
C3 in GBM
- EM: No deposits; GBM disruptions; fibrin
Idiopathic RPGN
- Clinical presentation: RPGN
- Pathogenesis" Anti-GBM immune complex; p-ANCA
- LM: Diffuse proliferative GN; focal necrosis' crescents - IF: Linear IgG and
C3 in GBM; Negative or Equivocal
- EM: Deposits may or may not be present.
No deposits
Membranous GN
- Clinical presentation: Nephrotic Syndrome
- Pathogenesis: antibody mediated
- LM: Diffuse capillary wall thickening; spikes (PASM) and domes (Trichrome)
- IF: Granular IgG and C3; diffuse
- EM: Subepithelial deposits
Focal Segmental Glomerulosclerosis (FSGSI
- Clinical presentation: Nephrotic syndrome; non-nephrotic proteinuria
- Pathogenesis: Unknown
- LM: Focal and segmental sclerosis and hyalinosis
- IF: Focal; IgM and C3
- EM: Loss of foot processes; epithelial denudation
- Membranoproliferative GN MPGN Type I
- Clinical presentation: Nephrotic Syndrome
- Pathogenesis: Immune Complex - LM: Mesangial proliferation; GBM
thickening and splitting
- IF: Granular IgG and C3; Cl and C4 in GBM
- EM: Subendothelial deposits
- Membranous Proliferative GN MPGN Type II
- Clinical presentation: Hematuria; Chronic renal failure.
- Pathogenesis: Autoantibody; alternative complement pathway activation
- LM: Mesangial proliferation; GBM thickening and splitting
- IF: Granular C3 IgG, no Cl or C4
- EM: Dense deposit disease
IgA Nephropathv (Berger's Disease)
- Clinical presentation: Recurrent hematuria and/or proteinuria
- Pathogenesis: Unknown
- LM: Focal proliferative GN' mesangial proliferative GN
- IF: Granular IgA and IgG, M, and C3 in mesangium - EM: Mesangial and
paramesangial dense deposits
Minimal Change Disease (MCD1
- LM: Normal
- IF: No deposits
- EM: Diffuse loss of foot processes of epithelial cells.
Diabetes Mellitus:
- End-stage renal disease occurs in as any as 30% of IDDM (type I) and accounts for
22% of the death in patients younger than 40 years of age
- In the renal arterioles: Arteriolosclerosis
- In the renal medulla: Papillary necrosis
Diabetic Glomerulosclerosis
- In the glomeruli:
- Capillary basement membrane thickening
7 Diffuse glomerulosclerosis: most common lesion but not pathognomonic
- Nodular glomerulosclerosis, intercapillary glomeruloscle - rosis or Kimmelstiel-Wilson:
less common lesion but it is pathognomonic of DM.
UNIVERSIDAD CENTRAL DEL CARIBE
PATHOLOGY
THE KIDNEY
Robbins 7ed
Congenital Anomalies: congenital renal disease can be hereditary but is most often the result of
an acquired developmental defect that arises during gestation.
Agenesis
Hypoplasia - Six or fewer renal lobes and pyramids
Ectopic
Horseshoe- Fusion of the upper or lower poles- 90% fused at the lower pole; 1/500 to
1000 autopsies.
CYSTIC DISEASES OF THE KIDNEY
A heterogeneous group comprising: See table 20-2
Hereditary
Developmental but nonhereditary
Acquired
Cystic renal dysplasia abnormality in metanephric differentiationpersistence in
the kidney of abnormal structures as cartilage, undifferentiated mesenchyme, and immature
collecting ductules, and abnormal lobar organization. Unilateral or bilateral, always cystic.
Autosomal dominant (adult) Polycystic kidney disease multiple expanding
cysts of both kidneys, 1/400 to 1000 live births , 10% of cases of chronic renal failure.
Autosomal dominant with high penetrance. Usually bilateral.
Three separate genes PKD1-16p13.3 85% of cases polycystin I= complex cell membrane
protein.
PKD2 4q13-23,polycystin 2integral membrane protein
PKD3 HAS YET TO BE MAPPED.
The kidneys are usually bilaterally enlarged up to 4 kg for each kidney. The external
surface appears to be composed of a mass of cysts. They may be filled with clear serous
fluid to hemorrhagic fluid.
Some of the patients remain asymptomatic until renal insufficiency or the dilatation of the
cysts may produce pain, hematuria, protinuria, polyuria, and hypertension.
40% of patients have one to several cysts in the liver usually asymptomatic, intracraneal
berry aneurysm in the circle of Willis, and/or mitral valve prolapse.
Possible mechanism of cyq-formation in polycystic kidney disease:
Mutation in polycystin 1,2
Defects in cell-cell and cell-matrix interactions Altered
tubular epithelial zrowth and differentiation
Nodular Hyperplasia:
20% of men 40 years; 70% of men 60 years; 90% of men 79 yrs.
Asymptomatic in most patients.
? effects of androgens--- dihydrotestosterone --- via 5 alpha -reductase.
Frequency, nocturia, difficulty starting, and stopping.
Acute retention and chronic stasis
Morphology: periurethral portion. Hyperplasia of glands and fibromuscular
stroma.
Squamous metaplasia, infarcts, and cystic dilation.
Carcinoma of Prostate
Most common form of cancer in men.
Second leading cause of cancer death among men.
Men > 50 years.
Blacks > white; rare Asian
Etiology: unknown--hormonal influences, genetic factors, and -
environmental factors-diet-.
Morphology: 70% peripheral part--- posterior region. Stony hard area
Adenocarcinomas-- well to poorly differentiated sheets and cords. Closely spaced;
single layer of epithelial cells: invasion of vascular channel and perineural spaces.
Poorly demarcated, firm, gritty foci.
Advanced cases infiltrate the seminal vesicle and urinary bladder; invasion of
the rectum uncommon
Lymphatic metastases initially in obturator nodes. followed to perivesical.
hypogastric, iliac, presacral, and para-aortic.
Hematogenous dissemination bone osteoblastic metastases. Prostatic
intraepithelial neoplasia is common adjacent ducts, presumably precursor of invasive
carcinoma.
Grading degree of differentiation, nuclear atypia, growth pattern--
predict the biologic behavior of carcinoma; Gleason system.
Staging therapy and prognosis
DNA ploidy , additional prognostic information--- aneuploid and tetraploid worst than
diplod
Serum prostatic acid phosphatase useful in diagnosis and staging.
PSA = PROSTATIC SPECIFIC ANTIGEN elevated in localized and advanced cancer; lesser
elevation may be seen in prostatic hyperplasia. Read Robbins 7th 1053- 1058
The ratio of free PSA to that bound to alpha -antichymotrypsin is consider useful in
distinguishing carcinoma from benign diseases. The percentage of free PSA is lower in
prostatic cancer.
Revised: 2009